Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

81.6 3.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

80.39

Max

81.95

Pagrindiniai rodikliai

By Trading Economics

Pajamos

136M

-93M

Pardavimai

43M

246M

Pelnas, tenkantis vienai akcijai

-0.3

Pelno marža

-37.599

Darbuotojai

1,402

EBITDA

-4.7B

-69M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+27.89% upside

Dividendai

By Acuity

Kitas uždarbis

2026-07-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.7B

14B

Ankstesnė atidarymo kaina

78.56

Ankstesnė uždarymo kaina

81.6

Naujienos nuotaikos

By Acuity

50%

50%

163 / 342 reitingas Healthcare

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-02 23:41; UTC

News
Social Media

Meta shares rise in after-market trading as CEO Zuckerberg highlights upcoming AI benefits and announces new application Pocket, despite some setbacks.

2026-07-02 23:32; UTC

News
Social Media

Microsoft launches AI initiative Microsoft Frontier Company with $2.5 billion backing. Shares are higher in after-market trading, continuing the broader software sector's upward trend.

2026-07-02 23:31; UTC

News
Social Media
ETF Constituents
Correlated Moves

The Nasdaq 100 Index is higher in after-market hours, buoyed by U.S. jobless data and positive contributions from Microsoft, Meta, and Texas Instruments.

2026-07-02 23:26; UTC

News

O'Reilly Automotive's $10 billion bid for Genuine Parts' division coincides with a decline in shares during after-market trading. Genuine Parts' shares rose significantly.

2026-07-02 23:26; UTC

News

Qualcomm shares are higher in after-market hours despite Elon Musk's denial of a partnership with SpaceX and removal from Russell indexes.

2026-07-02 23:16; UTC

Correlated Moves
News
Macro News
ETF Constituents

Vanguard Information Technology ETF gains after-hours, supported by positive contributions from Microsoft and Texas Instruments, following favorable U.S. jobless data.

2026-07-02 23:16; UTC

News

Microchip Technology Inc shares are higher in after-market trading, despite concerns over AI-driven chip demand and a recent pullback in the Philadelphia Semiconductor Index.

2026-07-02 23:12; UTC

News

Applied Materials shares advanced in after-hours trading, buoyed by positive equity market sentiment and gains in European indices like the DAX.

2026-07-02 23:11; UTC

News
Macro Event
Correlated Moves

The USD/CZK exchange rate is lower today, reflecting recent U.S. labor market data and broader market sentiment influencing currency movements.

2026-07-02 23:11; UTC

Macro Event
News

The USD/PLN exchange rate is lower today, reflecting a decline since Wednesday's close amid mixed U.S. labor market data and unusual volatility.

2026-07-02 23:11; UTC

News
Social Media
Correlated Moves

The EUR/HKD exchange rate is rising, supported by U.S. Dollar weakness after disappointing nonfarm payroll data and positive GBP/USD movements.

2026-07-02 23:11; UTC

News
Macro Event

The U.S. Dollar weakened against the Danish Krone following disappointing June nonfarm payroll data, which showed only 57,000 jobs added.

2026-07-02 23:11; UTC

News
Social Media
Correlated Moves

Weakness in the U.S. Dollar, following disappointing payroll data, supports gains in GBP/HKD during Thursday's session. The asset is higher since Wednesday's close.

2026-07-02 23:11; UTC

News
Macro Event
Correlated Moves

The USD/NOK exchange rate is lower, influenced by weaker U.S. job growth and correlated declines in USD/CAD. Volatility remains notable during Thursday's session.

2026-07-02 23:11; UTC

Correlated Moves
News

Bitcoin remains higher despite SBI Crypto's cessation of mining operations. Earlier in the session, it pulled back from a peak amid significant volatility.

2026-07-02 23:06; UTC

News

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

2026-07-02 23:06; UTC

Correlated Moves
News

Gold trades slightly higher in after-market hours, supported by a modest rise in silver and tempered rate hike expectations following a weaker jobs report.

2026-07-02 23:01; UTC

Macro Event
News

The USD/ZAR exchange rate is lower today, impacted by weaker U.S. Non-Farm Payrolls data revealing only 57,000 jobs added in June.

2026-07-02 22:51; UTC

Macro Event
News

The Nikkei 225 Index declined in after-market hours, pressured by a sell-off in semiconductor shares and strengthened yen amid government intervention expectations.

2026-07-02 20:13; UTC

ETF Constituents
News

Vanguard Large-Cap ETF declines after market close, influenced by broader market conditions and weaker U.S. jobs data. Holdings like Google and Johnson & Johnson also posted losses.

2026-07-02 20:13; UTC

News
Correlated Moves

The Japanese yen strengthened to a two-week high against the U.S. dollar amid global uncertainties, while Invesco Currencyshares Japanese Yen Trust is trading roughly flat after hours.

2026-07-02 20:07; UTC

Correlated Moves
News
Macro Event

The USD/HUF exchange rate is declining amid disappointing US job growth and a weaker US Dollar Index, with notable intraday volatility.

2026-07-02 20:06; UTC

News

Liberty Global shares are higher as Liberty Latin America is added to several Russell Growth indices, potentially boosting visibility to passive funds and investors.

2026-07-02 20:06; UTC

Correlated Moves
News
Macro Event

The USD/SGD exchange rate is lower today, reflecting pressure from weaker U.S. job growth data and a declining U.S. Dollar Index.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices are higher, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices rise amid weaker U.S. jobs data, which reported only 57,000 new jobs. Easing oil prices and rising silver also support gold's appeal.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices are higher today, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices are higher, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026-07-02 20:05; UTC

Correlated Moves
Social Media
ETF Constituents
News

The Communication Services Select Sector SPDR Fund is underperforming, reflecting a decline in the Communications sector. The fund remains roughly flat since Wednesday's close.

2026-07-02 20:05; UTC

News
Social Media

Tesla Inc's stock is declining amid profit-taking despite strong delivery figures. Analysts raised the price target to $430, but investor concerns persist.

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

27.89% į viršų

12 mėnesių prognozė

Vidutinis 104.61 USD  27.89%

Aukščiausias 130 USD

Žemiausias 75 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

17

Pirkti

2

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

163 / 342 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat